← Eichor
Condition: Apoptosis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Apoptosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On
Phase 2 · 2 location(s) · Fudan University · NCT05281003BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Phase 2 · 33 location(s) · SCRI Development Innovations, LLC · NCT06773910Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Hea
Phase N/A · 1 location(s) · Centre Paul Strauss · NCT05328024Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therap
Phase N/A · 1 location(s) · Centre Hospitalier Régional d'Orléans · NCT04160455Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07209189Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease
Phase 2/Phase 3 · 1 location(s) · Mostafa Bahaa · NCT05986136A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0
Phase 2 · 38 location(s) · Merck Sharp & Dohme LLC · NCT06961006A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First
Phase 1/Phase 2 · 51 location(s) · Merck Sharp & Dohme LLC · NCT06469944Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patient
Phase 2 · 1 location(s) · Qian Chu · NCT06001151Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT06147960A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · 296 location(s) · AstraZeneca · NCT06868277Novel Therapeutic Approach for Human T-cell Malignancies
Phase N/A · 2 location(s) · Istituto Oncologico Veneto IRCCS · NCT06600568Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Phase 2 · 1 location(s) · Mark Garzotto, MD · NCT03753243A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 287 location(s) · AstraZeneca · NCT06627647Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
Phase N/A · 2 location(s) · Tianjin Medical University · NCT07618936Autophagy/Apoptosis Balance in Placental Vascular Pathologies
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT06779916Volrustomig Priming Regimens Exploratory Phase II Platform Study
Phase 2 · 77 location(s) · AstraZeneca · NCT06448754Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells an
Phase 1 · 2 location(s) · Thomas Aagaard Rasmussen · NCT07481175Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Phase N/A · 7 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00246857Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06228066A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · 402 location(s) · Pfizer · NCT07144280Tislelizumab in People With Colorectal Cancer
Phase 2 · 3 location(s) · Memorial Sloan Kettering Cancer Center · NCT06529523A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Al
Phase 3 · 261 location(s) · Merck Sharp & Dohme LLC · NCT06952504Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among P
Phase 1/Phase 2 · 1 location(s) · University of Aarhus · NCT05668026A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung C
Phase 3 · 225 location(s) · Merck Sharp & Dohme LLC · NCT06345729Curcumin Supplementation in Cervical Cancer
NA · 1 location(s) · National Institute of Cancerología · NCT06080841A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · 317 location(s) · Merck Sharp & Dohme LLC · NCT06966700Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Phase 2 · 30 location(s) · BeiGene · NCT03736889Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patie
Phase 1 · 45 location(s) · BioNTech SE · NCT05142189
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.